Autres langues Theralase Technologies Inc.

Actions

TLT

CA88337V1004

Marché Fermé - Toronto S.E. Autres places de cotation 18:47:19 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,16 ^CAD	-3,03 %		0,00 %	-8,57 %

05/04	Theralase Technologies Inc. reçoit un brevet canadien pour un vaccin contre le cancer	CI
27/03	Theralase Technologies Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Theralase Technologies Inc. announced that it has received CAD 0.7502 million in funding	24/04
Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent	05/04
Theralase Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Theralase Technologies Donates Cool Laser Therapy Technology to Aid in R&D of Treatment for Parkinson's Disease	12/02
Theralase Technologies shares update on Phase II Bladder Cancer study	08/02
Theralase Technologies Closes C$1.2-Million Private Placement of Share Units	05/02
Theralase Technologies Inc. announced that it has received CAD 1.200001 million in funding	05/02
Theralase Technologies Provides Update on Phase II Bladder Cancer Clinical Study	15/01
Theralase Technologies Inc. Provides Update on Phase II Bladder Cancer Clinical Study	15/01
Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA	04/12
Theralase Technologies Raises C$1.17 Million in a Private Placement of Share Units	29/11
Theralase Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11
Theralase Technologies Inc. announced that it has received CAD 1.17 million in funding	29/11
Theralase Technologies Raising up to C$1.5 Million in a Private Placement of Share Units	17/11
Theralase Technologies Inc. announced that it expects to receive CAD 1.5 million in funding	17/11
Theralase Technologies : Amended LIFE Offering Document	27/10/23
Theralase® Technologies Inc. Announces That It Has Been Granted Clinical Trial Application Amendment by Health Canada Through Receipt of A No Objection Letter for the Optimization of the Phase Ii Non-Muscle Invasive Bladder Cancer Clinical Study	23/10/23
Theralase Technologies Inc. Provides Update on Bladder Cancer Clinical Study	16/10/23
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	09/10/23
Theralase Technologies Inc. Files US Patent for Enhanced Immunotherapy	05/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Theralase Technologies Inc.

Actions

TLT

CA88337V1004

Autres langues

Filtres